Therapeutic Drug Monitoring (TDM) & Managing Narrow Therapeutic Index (NTI) Drugs (Clinical Treatise 2020)
Narrow therapeutic index drugs require precise serum concentration assays paired with Bayesian dosing algorithms to prevent catastrophic toxicity while ensuring clinical efficacy.
Pharmacological Mechanism & Kinetic Schema
The Steady-State Equilibrium Principle
Upon repeated dosing at constant intervals (tau), drug accumulation occurs until the rate of elimination matches the rate of administration. True steady-state is achieved strictly after 4 to 5 elimination half-lives (t1/2). Serum blood draws executed before steady-state attainment yield dangerously misleading pharmacokinetic interpretations.
Vancomycin AUC/MIC Guided Monitoring
Consensus clinical guidelines have shifted from isolated trough monitoring (15–20 mg/L) to 24-hour area-under-the-curve over minimum inhibitory concentration (AUC24/MIC) targets of 400 to 600 mg·h/L. This approach maximizes bactericidal killing against MRSA while dramatically reducing the incidence of acute kidney injury (AKI).
Aminoglycoside Extended-Interval (Once-Daily) Dosing
Exploiting concentration-dependent bactericidal killing (Cmax/MIC >= 8–10) and the post-antibiotic effect (PAE), consolidated single-dose regimens achieve high therapeutic bactericidal spikes while allowing extended washout periods where trough levels drop below 1 mg/L, preventing saturable endocytic uptake into renal proximal tubular cells.
Clinical Pharmacologist & Biochemist · Specialist in Pharmacokinetics & Hospital Pharmacotherapy · Published on September 09, 2020 at 01:10
